Venus Remedies has outlicensed Elores to a South Korean market leader after its patent grant from Companies and Intellectual Property Registration Office (CIPRO) from Republic of South Korea. The dossier for this product is already under evaluation by KFDA. Venus and Korean major Goodwills Co were in talks and negotiations for this deal from a long time. South Korean major is expecting to launch this product in 2014 after approval from Korean FDA. A bridging clinical trial has already been initiated on Korean population and which is currently running across 6 leading hospitals of Seoul, the capital city of South Korea.
Goodwills Co will have exclusive marketing rights of the product in South Korea till patent validity in 2025. ELORES is expected to be launched by mid of 2014 after getting due regulatory approvals from KFDA making it second deal of its kind in a year. Further, grant of the Patent is another testimony to the merits and uniqueness of Elores.
Elores is an antibiotic product meant for multi-drug resistant infections in ICU, specially in hospital acquired infection where the rise in resistance reported to the extent of >70% in Asia Pacific region. ELORES is a novel antibiotic adjuvant entity (AAE) to combat antimicrobial resistance caused by ESBL producing strains, product is effective against Metallo betalactamases (MBL) producing pathogens which are not susceptible to most of the existing antibiotics.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: